A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens

Trial Profile

A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
    • 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Results (n=118) of exploratory analysis assessing whether incidences of irAE decreases if D with or without T is given with CT or CS, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top